<unk>  is a histone deacetylase inhibitor that is FDA approved for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.   Common adverse reactions include diarrhea, fatigue, nausea, thrombocytopenia, anorexia and dysgeusia.
Vorinostat
Febuxostat
Levoleucovorin
Carfilzomib
Rasburicase
Dabrafenib mesylate
Sunitinib
Ixazomib